Every Form 4 that Colgate-Palmolive Company (CL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CL filings page.
Colgate-Palmolive Co. director Lorrie M. Norrington acquired 300 shares of Common Stock on October 1, 2026, at $87.42 per share. The shares were directly held, bringing her reported direct position to 43,310 shares after the transaction. The transaction represented a portion of her annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
Colgate-Palmolive director Brian Newman acquired 214 shares of common stock on October 1, 2026, at a reported $87.42 per share. The acquisition reflects a portion of his annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors. He directly held 8,058 shares following the acquisition and reported 36 shares indirectly through a Family Trust.
Colgate-Palmolive director John P. Bilbrey acquired 271 common shares on October 1, 2026, at a reported $87.42 per share. The acquisition represented a portion of his annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
COLGATE PALMOLIVE CO (CL) reported that Chairman, President & CEO Noel R. Wallace received equity awards on September 16, 2026. He was granted 205,197 stock options to buy Common Stock at an exercise price of $87.02 per share, expiring September 16, 2036, under the company’s incentive compensation plan; these options become exercisable in equal annual installments over three years beginning on the first anniversary of the grant date. He also received 29,649 restricted stock units, which vest in equal one-third installments on each of the first, second and third anniversaries of the grant date. Following these awards, he holds 379,700 shares of Common Stock directly, plus indirect holdings of 54,868 shares through the issuer’s 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust. No Rule 10b5-1 trading plan is reported for these grants.
COLGATE PALMOLIVE CO (CL) reported that Shane Grant, COO, Americas, received new equity awards on September 16, 2026. He was granted stock options for 50,902 shares of common stock at an exercise price of $87.02 per share, expiring September 16, 2036, vesting in one‑third increments beginning on the first anniversary of the grant date. He also received a restricted stock unit award covering 7,355 shares, which vests in three equal annual installments on the first, second and third anniversaries of the grant date. Following these awards, he directly holds 79,503 shares of common stock and 50,902 stock options; no Rule 10b5‑1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reports that Chief Operating Officer Panagiotis Tsourapas received equity awards on September 16, 2026. He was granted 31,814 stock options to buy common stock at an exercise price of $87.02 per share, expiring on September 16, 2036, vesting in one-third increments beginning on the first anniversary of the grant date.
He also received a restricted stock unit award of 4,597 units of common stock, vesting in equal one-third installments on each of the first, second and third anniversaries of the grant. After these awards, he holds 11,447 shares of common stock directly, plus 4,619 shares held through the issuer’s 401(k) plan trustee and 64,901 shares held indirectly through a trust. No Rule 10b5-1 trading plan is reported for these awards.
COLGATE PALMOLIVE CO (symbol: CL) is the issuer of record for a Form 4 filing submitted to the SEC. SUTULA STANLEY J III reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO (CL) reported that Chief Financial Officer Stanley J. Sutula III received new equity awards on September 16, 2026. He was granted 55,674 stock options to buy common shares at $87.02 per share, expiring September 16, 2036, and 8,045 restricted stock units that vest in three equal annual installments. Following these awards, he holds 79,029 common shares directly and 331 shares indirectly through the issuer’s 401(k) plan. No Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that Chief Growth Officer John Hazlin received equity awards on September 16, 2026. He was granted stock options for 27,042 shares of common stock at an exercise price of $87.02 per share, expiring September 16, 2036, which become exercisable in one-third increments beginning on the first anniversary of the grant date. He also received a restricted stock unit award of 3,908 shares that vests in equal one-third installments on each of the first, second and third anniversaries of the grant date. After these awards, he holds 27,021 common shares directly and 5,513 shares indirectly through the issuer’s 401(k) plan, and no Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (symbol: CL) is the issuer of record for a Form 4 filing submitted to the SEC. Massey Sally reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO (CL) reported that Chief People Officer Sally Massey received equity awards on September 16, 2026. She was granted 23,065 stock options to buy common shares at $87.02 per share, expiring September 16, 2036, and 3,333 restricted stock units that vest in three equal annual installments. After these awards, she holds 15,397 common shares directly and 8,199 common shares indirectly through the issuer’s 401(k) plan trustee, in addition to the new option grant. No Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that its CLO and Secretary, Betsy Fishbone, received equity awards on September 16, 2026. She was granted a stock option for 15,271 shares of common stock at an exercise price of $87.02 per share, expiring September 16, 2036, which becomes exercisable in one-third increments beginning on the first anniversary of the grant date.
She also received a restricted stock unit award of 2,207 shares that vests in equal one-third installments on each of the first, second, and third anniversaries of the grant date, increasing her directly held common stock to 16,050 shares. In addition, 50 common shares are held indirectly by a family member and 8,336 common shares are held indirectly through the issuer's 401(k) plan trustee.
COLGATE PALMOLIVE CO (symbol: CL) is the issuer of record for a Form 4 filing submitted to the SEC. Malcolm Gregory reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO (CL) reported that EVP and Controller Gregory Malcolm received equity awards on September 16, 2026. He was granted 7,477 stock options to buy common shares at $87.02 per share, expiring September 16, 2036, vesting in one-third increments starting one year after the grant date. He also received a restricted stock unit award of 1,081 common shares, vesting in equal one-third installments on each of the first, second and third anniversaries of the grant date. After these awards, he holds 14,162 common shares directly and 8,650 common shares indirectly through the issuer’s 401(k) plan trustee; no Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that Chairman, President & CEO Noel R. Wallace disposed of common shares solely to cover tax obligations from equity compensation. On September 11–13, 2026, a total of 12,479 shares were withheld at $86.80 per share to pay tax on vesting restricted stock units under the issuer's incentive compensation plan. No Rule 10b5-1 trading plan is reported. Indirect holdings after these events include shares held by the issuer's 401(k) plan trustee and family trusts.
COLGATE PALMOLIVE CO (CL) reported that officer Panagiotis Tsourapas disposed of common stock through tax-related withholdings tied to equity compensation. On September 11, 12, and 13, 2026, a total of 2,224 shares were withheld at $86.80 per share to pay tax liabilities incident to the vesting of restricted stock units under the issuer's incentive compensation plan; no open-market purchases or sales are reported. As of September 11, 2026, Tsourapas also held common stock indirectly, including 4,619 shares through the issuer's 401(k) plan trustee and 64,901 shares held by a trust. No transactions are reported as made under a Rule 10b5-1 trading plan.
COLGATE PALMOLIVE CO (CL) reported that Chief Financial Officer Stanley J. Sutula III had shares of common stock withheld over September 11–13, 2026 to cover tax liabilities arising from the vesting of restricted stock units under the company’s incentive compensation plan. In total, 3,509 shares were withheld at $86.80 per share. After these transactions, an indirect holding of 331 shares remains in an account held by the issuer’s 401(k) plan trustee.
COLGATE PALMOLIVE CO (CL) reported that Chief People Officer Sally Massey had Colgate common shares withheld on September 11, 12 and 13, 2026 to pay tax liabilities arising from vesting restricted stock units under the company’s incentive compensation plan.
Across the three dates, 1,796 shares of common stock were withheld at $86.80 per share. The filing also reports an indirect holding of 8,199 common shares held through the issuer’s 401(k) plan trustee. No Rule 10b5-1 trading plan is reported for these transactions.
COLGATE PALMOLIVE CO (CL) reported that EVP and Controller Malcolm Gregory had shares of common stock withheld on September 11–13, 2026 to cover tax liabilities arising from the vesting of restricted stock units under the company’s incentive compensation plan. These transactions used share withholding rather than open-market sales, and no Rule 10b5-1 plan is reported.
COLGATE PALMOLIVE CO (CL) reported that Chief Growth Officer John Hazlin had shares of common stock withheld on three dates in September 2026 to pay tax liabilities associated with vesting restricted stock units under the issuer's incentive compensation plan. The withholding totaled 1,587 shares at $86.80 per share. Hazlin also reports 5,513 shares held indirectly through the issuer's 401(k) plan trustee. No Rule 10b5-1 trading plan is reported for these transactions.
COLGATE PALMOLIVE CO (CL) reported that Shane Grant, its COO, Americas, had 622 shares of common stock withheld on September 11, 2026 to pay tax liability related to the vesting of restricted stock units under the company’s incentive compensation plan at a reference price of $86.80 per share. After this tax-withholding disposition, he directly holds 72,148 shares of Colgate-Palmolive common stock. No Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that Betsy Fishbone, CLO and Secretary, had a total of 1,207 shares of common stock withheld between September 11 and September 13, 2026, at $86.80 per share to pay tax liabilities related to the vesting of restricted stock units under the company’s incentive compensation plan.
After these transactions, indirect holdings reported include 50 shares held by a family member and 8,336 shares held through the issuer’s 401(k) plan trustee. No Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that officer Panagiotis Tsourapas, COO, CD, EMEA, APac, Skin, indirectly sold 10,000 shares of common stock on August 24, 2026 in a sale coded "S". The weighted average sale price was $92.0477 per share, with individual trades executed between $92.00 and $92.12 per share. After this transaction, an associated trust held 64,901 shares, which includes 12,661 shares that had previously been reported as directly beneficially owned. Separate holding entries show Tsourapas directly holding 9,074 shares and indirectly holding 4,619 shares through the issuer's 401(k) plan trustee.
Colgate-Palmolive director John T. Cahill reported an option exercise-and-sale on August 6, 2026. He exercised stock options for 4,170 shares of common stock at an exercise price of $71.56 per share and sold 4,170 shares at a weighted average price of $93.3712–$93.39, with part of the proceeds delivered to Colgate-Palmolive to pay the option exercise price. After these transactions, he continues to hold 36,357 shares indirectly through a trust.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace exercised stock options covering 322,042 shares of common stock at an exercise price of $72.2900 per share on August 4–5, 2026, then sold an equal number of shares at weighted average prices of $91.9179 and $92.5215, with a portion of the sale proceeds delivered to the issuer to pay the option exercise price and related tax withholding.
Reported indirect holdings include 54,868 shares held by the issuer's 401(k) plan trustee, 52,000 shares held by a spouse trust, and 335 shares held by another trust.
Colgate-Palmolive director Lorrie M. Norrington acquired 293 shares of common stock at $89.45 per share as a grant under her compensation program. The footnote explains this represents a portion of her annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors. Following this award, she directly holds 42,769 shares of Colgate-Palmolive common stock, indicating this is a small, routine, compensation-related transaction rather than an open-market purchase.
COLGATE PALMOLIVE CO director Brian Newman reported a routine compensation-related equity grant. He acquired 209 shares of common stock at $89.45 per share as a grant or award, representing a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
Following this grant, Newman directly holds 7,831 shares of Colgate-Palmolive common stock. He is also shown with indirect ownership of 36 shares held by a family trust. These entries reflect compensation and holding disclosures rather than open-market buying or selling.
Colgate-Palmolive director John P. Bilbrey reported a compensation-related share award. He acquired 265 shares of Common Stock at $89.45 per share as a grant or award, increasing his direct holdings to 40,229 shares. A separate entry reflects 4,719 shares held indirectly by a trust. The footnote explains that a portion of his annual cash retainer was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, indicating this was part of routine director compensation rather than an open-market purchase.
Colgate-Palmolive COO, Americas Shane Grant reported a tax-related share disposition tied to equity compensation. On this Form 4, 23,347 shares of Common Stock were withheld at $90.66 per share to cover tax obligations from the vesting of restricted stock units under the company’s incentive compensation plan.
These shares were not sold in the open market but withheld by the issuer for tax payment. After this withholding, Grant directly holds 72,481 shares of Colgate-Palmolive common stock, indicating he retains a substantial equity position following the RSU vesting event.
COLGATE PALMOLIVE CO executive Malcolm Gregory reported an open-market sale of 2,300 shares of Common Stock at $88.44 per share. The sale was a direct transaction and left him with 13,598 shares held directly. He also has 8,599 shares held indirectly through the issuer's 401(k) Plan trustee.
COLGATE PALMOLIVE CO director Brian Newman reported routine equity awards. He received an annual director stock grant of 2,075 shares of common stock, bringing his direct holdings to 7,621 shares. These shares were granted under the company’s incentive compensation plan.
Newman was also granted stock options for 2,424 shares at an exercise price of $86.7400 per share, expiring on May 11, 2034. The options become exercisable in equal annual installments over three years starting on the first anniversary of the May 11, 2026 grant date. In addition, 36 shares are held indirectly through a family trust.
COLGATE PALMOLIVE CO director Kimberly A. Nelson received new equity compensation awards. On May 11, 2026, she acquired 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing her direct holdings to 11,634 shares.
On the same date, she also received a stock option for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. This option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the grant date. The filing also lists additional indirect holdings through a trust, spouse, and a family trust.
Colgate-Palmolive director Martina Hundmejean received equity awards as part of her annual compensation. She was granted 2,075 shares of Common Stock at no cost, credited to a stock unit account under the company’s incentive compensation plan, bringing her direct holdings to 16,206 shares.
She also received a stock option for 2,424 shares of Common Stock with an exercise price of $86.74 per share. The option vests in equal annual installments over three years, starting on the first anniversary of the May 11, 2026 grant date. These are compensation-related grants, not open-market purchases or sales.
Colgate-Palmolive director Harris C. Martin received new equity awards. On May 11, 2026, he was granted 1,556 shares of Common Stock as an annual director stock grant under the company’s incentive compensation plan.
He was also granted stock options for 2,424 shares of Common Stock with an exercise price of $86.74 per share, expiring on May 11, 2034. These options become exercisable in equal annual installments over three years beginning on the first anniversary of the grant date. Following the stock grant, he directly holds 24,517 common shares, plus the newly granted options.
Colgate-Palmolive director Lorrie M. Norrington reported compensation-related equity awards. She received an annual director stock grant of 2,075 shares of common stock credited to a stock unit account under the company’s incentive compensation plan, bringing her direct common stock holdings to 42,312 shares.
She was also granted a stock option covering 2,424 shares of common stock at an exercise price of $86.74 per share. This option expires on May 11, 2034 and becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date.
Colgate-Palmolive director Lisa Edwards received routine equity awards as part of her compensation. She was granted 2,075 shares of common stock and 2,424 stock options on May 11, 2026 under the company’s incentive compensation plan. After the grant, she directly owns 18,182 common shares.
The options allow her to buy 2,424 common shares at an exercise price of $86.74 per share and expire on May 11, 2034. They become exercisable in equal annual installments over three years, starting on the first anniversary of the grant date.
COLGATE PALMOLIVE CO director John T. Cahill reported routine equity compensation awards. On May 11, 2026, he received an annual director stock grant of 2,075 shares of common stock, increasing his directly held shares to 28,216.
He also received an annual director stock option grant for 2,424 shares of common stock at a conversion price of $86.74 per share, with options vesting in equal annual installments over three years beginning on the first anniversary of the grant date and expiring on May 11, 2034. Separately, 36,357 shares are reported as held indirectly through a trust, which includes 2,019 shares previously reported as directly owned.
Colgate-Palmolive director Christopher S. Boerner reported equity compensation awards. He received an annual director stock grant of 1,383 shares of common stock under the company’s incentive compensation plan, leaving him with 1,383 common shares directly owned after the award.
He was also granted a stock option for 2,020 shares of common stock with an exercise price of $86.74 per share, expiring on May 11, 2034. The option becomes exercisable in equal annual installments over three years, beginning on the first anniversary of the May 11, 2026 grant date. These are compensation-related awards rather than open-market purchases or sales.
COLGATE PALMOLIVE CO director John P. Bilbrey reported routine equity compensation and updated holdings. He received a grant of 2,075 shares of Common Stock as an annual director stock grant under the issuer's incentive compensation plan, increasing his direct holdings to 39,820 shares. He also received an annual director stock option grant for 2,424 shares at an exercise price of $86.74 per share, expiring on May 11, 2034, which becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 11, 2026 grant date. In addition, a separate entry reflects 4,719 shares of Common Stock held indirectly by a trust.
Colgate-Palmolive Chief People Officer Sally Massey sold 8,599 shares of Common Stock in an open-market transaction. The sale took place on May 7, 2026 at a weighted average price of $87.4093 per share, with individual prices ranging from $87.36 to $87.53.
After the sale, Massey directly owned 13,785 shares of Colgate-Palmolive common stock and indirectly held 8,152 shares through the issuer’s 401(k) plan trustee.
NORRINGTON LORRIE M reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO director Lorrie M. Norrington received an equity award of 294 shares of Common Stock, valued at $89.05 per share. The award represents a portion of her annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, and increases her direct holdings to 40,160 shares.
Newman Brian reported acquisition or exercise transactions in this Form 4 filing.
Colgate-Palmolive director Brian Newman received 210 shares of Common Stock as a grant on April 1, 2026, at $89.05 per share. The award represents a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 5,534 shares of Colgate-Palmolive Common Stock. In addition, 36 shares are held indirectly through a family trust. This filing reflects routine director compensation rather than an open-market purchase or sale.
Colgate-Palmolive director John P. Bilbrey acquired 266 shares of Common Stock as a compensation award. The shares, valued at $89.05 each, represent a portion of his annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 37,665 Colgate-Palmolive shares and has an additional 4,719 shares held indirectly by a trust. The transaction reflects routine director compensation rather than an open-market purchase.
Colgate-Palmolive Chief Growth Officer John Hazlin reported equity compensation activity involving company common stock. On February 23, 2026, he acquired 12,803 shares through the vesting of performance-based restricted stock units granted under the incentive compensation plan. On the same date, 6,117 shares were disposed of at $97.10 per share to cover tax withholding related to that vesting. After these transactions, Hazlin directly owned 24,422 shares and indirectly held 5,452 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive’s Chief Legal Officer and Secretary Jennifer Daniels reported equity compensation activity in Common Stock. She acquired 25,742 shares through the vesting of previously granted performance-based restricted stock units that were earned under the company’s incentive compensation plan and settled in stock. To cover tax liabilities from this vesting, 12,351 shares were withheld at a price of $97.10 per share. After these transactions, she directly held 89,844 shares and indirectly held 1,837 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive EVP and Controller Malcolm Gregory reported equity award activity in company stock. He acquired 6,268 shares of Common Stock at a price of $0.0000 per share through the vesting of previously granted performance-based restricted stock units under the issuer's incentive compensation plan, which are settled solely in shares.
On the same date, 2,260 shares of Common Stock were disposed of at $97.1000 per share to cover tax liabilities associated with the PBRSU vesting. Following these transactions, he directly held 15,898 shares of Common Stock. In addition, 8,554 shares are held indirectly through the issuer's 401(k) plan trustee.
Colgate-Palmolive Chief Human Resources Officer Sally Massey reported stock-based compensation activity tied to performance awards. She acquired 16,805 shares of Common Stock at no cost from the vesting of previously granted performance-based restricted stock units earned under the company’s incentive plan. To cover tax obligations from this vesting, 8,206 shares were disposed of through a tax-withholding transaction at $97.10 per share, rather than an open-market sale. After these transactions, she directly owns 22,384 shares of Common Stock and indirectly holds 8,111 shares through the issuer’s 401(k) plan trustee.
Colgate-Palmolive Chief Financial Officer Stanley J. Sutula III reported equity compensation activity involving the company’s common stock. He acquired 38,678 shares on February 23, 2026 through the vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan.
On the same date, 19,746 shares were disposed of to cover tax withholding related to this vesting, rather than through an open-market sale. After these transactions, he held 74,320 shares directly and 328 shares indirectly through the issuer’s 401(k) plan trustee.
Colgate-Palmolive COO Panagiotis Tsourapas received 25,742 shares of Common Stock on February 23, 2026 from vesting of performance-based restricted stock units earned under the company’s incentive plan. No cash changed hands for this award.
On the same date, 13,081 shares were withheld at $97.10 per share to cover related tax liabilities. After these transactions, he directly holds 21,629 shares, plus 4,568 shares through the issuer’s 401(k) plan trustee and 62,240 shares held by a trust.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace reported equity award activity in company stock. On February 23, 2026, he acquired 136,710 shares of Common Stock at $0.00 per share through vesting of previously granted performance-based restricted stock units earned under the incentive compensation plan. On the same date, 68,252 shares at $97.10 per share were withheld to cover tax obligations related to this vesting, a non-open-market disposition. Following these transactions, he directly owned 361,921 shares of Common Stock. He also had indirect holdings of 54,281 shares through the issuer's 401(k) plan trustee, 52,000 shares via a spouse trust, and 335 shares via another trust.
Tsourapas Panagiotis reported multiple insider transaction types in a Form 4 filing for CL. The filing lists transactions totaling 150,000 shares at a weighted average price of $85.99 per share. Following the reported transactions, holdings were 19,938 shares.
Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share. A portion of the sale proceeds was delivered to the company to pay the option exercise price and related tax withholding. After these transactions, John directly owned 17,645 shares and indirectly held 5,452 shares through the issuer's 401(k) plan trustee.
Colgate-Palmolive executive Malcolm Gregory reported an employee stock option exercise and related share sale. On February 6, 2026, he exercised options for 12,747 shares of common stock at $76.41 per share under the company’s incentive compensation plan.
That same day, he sold 12,747 shares of Colgate-Palmolive common stock in market transactions at a weighted average price of $94.9103 per share, with individual trades ranging from $94.79 to $95.01. After these transactions, he directly owned 11,879 shares and held an additional 8,554 shares indirectly through the issuer’s 401(k) plan trustee.